(Sharecast News) - Sanofi reported strong fourth-quarter and full-year results for 2025 on Thursday, underpinned by robust growth from its blockbuster asthma and dermatology treatment Dupixent, while forecasting another year of profitable growth in 2026 despite lingering concerns over its pipeline and vaccine demand.
Fourth-quarter sales rose 13.3% at constant exchange...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE